摘要
目的:探讨生物标记物Presepsin(s CD14亚型)对评估呼吸机相关性肺炎(VAP)老年患者早期病情及预后的作用。方法:回顾性分析2014年1月至2016年1月接收的58例VAP老年患者的临床资料,根据预后将其分为存活组(36例)和死亡组(22例)。通过化学发光酶免疫测试法分别检测两组VAP发生前与治疗后第1 d、3 d、5 d的血清Presepsin水平、血白细胞(WBC)、C反应蛋白(CRP)水平。结果:两组VAP发生前血清Presepsin水平、WBC、CRP水平比较差异无统计学意义(P>0.05);存活组治疗第1 d、3 d、5 d时WBC与CRP水平与死亡组比较差异无统计学意义(P>0.05);存活组治疗第1 d、3 d、5 d时Presepsin水平低于死亡组(P<0.05)。结论:通过检测血清Presepsin水平,能够有效评估VAP老年患者的早期病情状态与预后情况,适于临床应用。
Objective：To deplore the effect of the biomarker presepsin（sCD14-ST） on assessing the early condition and the prognosis of elderly patients with ventilator associated pneumonia（VAP）.Methods：The clinical data of 58 elderly patients with VAP hospitalized from January 2014 to January 2016 were retrospectively analyzed.The patients were divided into the survival group（36 cases） and the death Group（22 cases） according to their prognosis.Serum levels of presepsin,white blood cells（WBC） and C-reactive protein（CRP） were measured by immunofluorescence assay before the incidence of VAP and on the 2nd,the 3th,and the 5th day after treatment.Results：There was no significant difference in levels of serum presepsin,WBC and CRP between the two groups before the incidence of VAP（P〉0.05）.There was no significant difference in WBC and CRP between the two groups on the 2nd,the 3th,and the 5th day after treatment（P〉0.05）.The levels of presepsin in the survival group were lower than those in the death group on the 2nd,the 3th,and the 5th day after treatment（P〈0.05）.Conclusion：serum presepsin levels can be used to evaluate the early condition and prognosis of elderly patients with VAP,suitable for clinical application.
出处
《包头医学院学报》
CAS
2018年第1期28-30,共3页
Journal of Baotou Medical College
